Key Highlights
- Zenkuda achieved its primary endpoint in Kodiak Sciences’ GLOW2 Phase 3 diabetic retinopathy trial
- Treatment resulted in 62.5% of patients achieving meaningful improvement compared to only 3.3% in the control arm
- The drug demonstrated an 85% reduction in sight-threatening complication risk versus sham through 48 weeks
- Trial reported zero instances of intraocular inflammation
- Company plans expedited Biologics License Application filing following positive data
Shares of Kodiak Sciences (KOD) climbed to $22.75 in response to the announcement, continuing a remarkable 656% rally over the previous twelve months, despite trading 18.6% lower for the current year.
Kodiak Sciences announced on March 26 that Zenkuda (tarcocimab tedromer) successfully achieved its primary endpoint in the GLOW2 Phase 3 clinical trial for diabetic retinopathy treatment.
The data demonstrated substantial superiority over the control group across all evaluated metrics.
Patients receiving Zenkuda showed a two-step or greater improvement on the diabetic retinopathy severity score (DRSS) at the 48-week mark in 62.5% of cases. The sham treatment group, by comparison, achieved this benchmark in only 3.3% of participants.
The findings reached statistical significance with strong confidence levels, successfully meeting the trial’s primary objective.
Vision-Threatening Event Prevention
The medication reduced the incidence of predefined sight-threatening events by 85% relative to sham treatment over 48 weeks. These events encompassed new or progressive proliferative diabetic retinopathy and center-involving diabetic macular edema.
Merely 2.4% of participants receiving Zenkuda experienced such complications, contrasted with 15.8% in the control cohort.
Regarding secondary outcomes, 13.7% of Zenkuda recipients demonstrated a three-step or greater DRSS improvement, while no sham-treated patients achieved this threshold.
These findings align closely with the preceding GLOW1 trial, which showed an 89% reduction in sight-threatening complication risk with Zenkuda.
GLOW2 served as a confirmatory investigation to GLOW1, broadening enrollment criteria to incorporate individuals with proliferative diabetic retinopathy and mild diabetic macular edema.
The treatment protocol involved Zenkuda administrations at study initiation, Week 4, Week 8, Week 20, and Week 44. By study conclusion, all participants had transitioned to a 6-month dosing interval.
Safety and Tolerability
The medication exhibited a favorable safety profile throughout the investigation. Researchers documented zero cases of intraocular inflammation, retinal vasculitis, or occlusive retinal vasculitis.
Cataract-related adverse events occurred at 2.3% in the Zenkuda cohort versus 1.6% in the sham group — rates consistent with baseline expectations for diabetic retinopathy patient populations.
GLOW2’s design incorporated patients receiving GLP-1 receptor agonist therapies, representing typical diabetic patient demographics. Approximately 46.1% of Zenkuda recipients and 42.4% of sham participants were utilizing GLP-1 medications.
Among Zenkuda-treated individuals on GLP-1 therapy, 60.0% achieved the primary endpoint, versus 64.3% of those not using GLP-1 medications — a minimal variance indicating negligible GLP-1 impact on treatment efficacy.
The company announced intentions to expedite its Biologics License Application submission schedule for Zenkuda following the encouraging GLOW2 outcomes.
H.C. Wainwright maintains a Buy recommendation on KOD stock with a $38 price objective. UBS similarly holds a Buy rating, assigning a $50 price target.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
